T1	Participants 163 229	The results of the treatment of 1022 ovarian cancers were reviewed
T2	Participants 355 393	ovarian cancers of stage 1 and stage 2
T3	Participants 617 668	50% of primarily inoperable stage 3 ovarian cancers
